Frias JP, et al. - In this double-blind, randomized clinical trial, researchers described the glycemic effectiveness and safety of initiation of the dipeptidyl peptidase-4 inhibitor sitagliptin during metformin dose escalation in patients with type 2 diabetes (T2D) not at glycated hemoglobin (HbA1c) goal on a sub-maximal dose of metformin. Participants in the study with HbA1c ≥58 mmol/mol and ≤97 mmol/mol (≥7.5% and ≤11.0%) while on 1,000 mg/day metformin were randomized to sitagliptin 100 mg once daily or placebo. There were a total of 458 participants treated. According to findings, the addition of sitagliptin at the time of metformin dose uptitration improved glycemic response and the ability to achieve their HbA1c goal in participants not at HbA1c goal on a sub-maximal dose of metformin, with comparable safety and tolerability vs metformin uptitration alone.